GDF-5 is expressed in long bones during embryonic development and postnatally in articular cartilage. Mutations in the GDF-5 gene have been implicated in Hunter-Thompson type dwarfism and in Grebe Syndrome, which is characterized by short stature, extra digits, and short and deformed extremities. The mature and functional form of GDF-5 is a homodimer of two 120 amino-acid polypeptide chain (monomers) linked by a single disulfide bond. Each GDF-5 monomer is expressed as the C-terminal part of a precursor polypeptide, which also contains a 27 amino acid signal peptide and a 354 amino acid propeptide. This precursor undergoes intracellular dimerization, and upon secretion it is processed by a furin-type protease. Recombinant Human GDF-5 (BMP-14/CDMP-1) is a 27.0 kDa homodimeric disulfide-linked protein consisting of two 120 amino acid polypeptide chains.
Manufactured using all Animal-Free reagents.
Growth/Differentiation Factor-5, Bone Morphogenetic Protein-14, Cartilage-Derived Morphogenetic Protein-1 (CDMP-1)
AA Sequence (monomer):
APLATRQGKR PSKNLKARCS RKALHVNFKD MGWDDWIIAP LEYEAFHCEG LCEFPLRSHL EPTNHAVIQT LMNSMDPEST PPTCCVPTRL SPISILFIDS ANNVVYKQYE DMVVESCGCR
≥ 98% by SDS-PAGE gel and HPLC analyses.
Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. The expected ED50 for this effect is 1.0-2.0 µg /ml.
Calculated Molecular Weight:
Endotoxin level is < 0.01 ng/ug of protein (< 0.1 EU/ug)
Not for human use.